Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.

Cascone, Tina

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. [electronic resource] - Journal of cellular physiology Sep 2008 - 698-707 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1097-4652

10.1002/jcp.21444 doi


Animals
Antibodies, Monoclonal--pharmacology
Antibodies, Monoclonal, Humanized
Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Boronic Acids--pharmacology
Bortezomib
Cell Line, Tumor--drug effects
Cetuximab
Dose-Response Relationship, Drug
Drug Combinations
Drug Synergism
Enzyme Activation
ErbB Receptors--antagonists & inhibitors
Gefitinib
Humans
Mitogen-Activated Protein Kinases--genetics
Piperidines--pharmacology
Proteasome Endopeptidase Complex--metabolism
Proteasome Inhibitors
Proto-Oncogene Proteins c-akt--genetics
Pyrazines--pharmacology
Quinazolines--pharmacology
Signal Transduction--physiology